AI assistant
Niagen Bioscience, Inc. — Director's Dealing 2022
Aug 13, 2022
32418_dirs_2022-08-12_aadd892f-aa10-4494-bba3-2f8b690f50d6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2022-08-11
Reporting Person: Gerber Brianna (SVP Finance / Interim CFO)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1238 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Employee Stock Options (right to buy) | $3.55 | 2028-11-30 | Common Stock (11140.0) | Direct | |
| Employee Stock Options (right to buy) | $3.84 | 2029-02-21 | Common Stock (22266.0) | Direct | |
| Employee Stock Options (right to buy) | $3.27 | 2030-02-25 | Common Stock (60000.0) | Direct | |
| Employee Stock Options (right to buy) | $4.92 | 2030-08-05 | Common Stock (10000.0) | Direct | |
| Employee Stock Options (right to buy) | $11.83 | 2031-03-14 | Common Stock (32000.0) | Direct | |
| Employee Stock Options (right to buy) | $2.67 | 2032-02-16 | Common Stock (56576.0) | Direct |
Footnotes
F1: 1,238 shares held by Jacob Gerber who is a spouse of Brianna Gerber.
F2: One-third of the shares subject to the option vested on September 17, 2017 and the remaining shares subject to the option have vested in a series of 24 equal monthly installments thereafter. The stock options are fully vested as of August 11, 2022.
F3: One-third of the shares subject to the option vested on February 21, 2020 and the remaining shares subject to the option have vested in a series of 24 equal monthly installments thereafter. The stock options are fully vested as of August 11, 2022.
F4: One-third of the shares subject to the option vested on February 25, 2021 and the remaining shares subject to the option are vesting in a series of 24 equal monthly installments thereafter.
F5: One-third of the shares subject to the option vested on August 6, 2021 and the remaining shares subject to the option are vesting in a series of 24 equal monthly installments thereafter.
F6: One-third of the shares subject to the option vested on March 15, 2022 and the remaining shares subject to the option are vesting in a series of 24 equal monthly installments thereafter.
F7: One-third of the shares subject to the option shall vest on February 17, 2023 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter.